WebJul 10, 2024 · Article CAS PubMed PubMed Central Google Scholar O’Neil BH, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. ... CheckMate-142 is the largest single-study report of combination immunotherpy with nivolumab and ipilimumab demonstrating high response rate and … WebApr 14, 2024 · 3.2 Overall survival and progression‐free survival in RCT. There are 3 phase III RCT studies (CheckMate 143, CheckMate 498, and CheckMate 548), involving 822 …
CheckMate-142 Update Simultaneously Published and Presented: …
WebNov 18, 2024 · The clinical activity of nivolumab in MSI-H/dMMR mCRC treated with prior chemotherapy was shown in a nivolumab cohort in the CheckMate 142 trial ( 11 ). A total of 74 patients were treated with nivolumab (3 mg/kg, every 2 weeks) and the ORR was 31.1% by investigator assessment. WebJun 5, 2024 · Nivolumab is the first PD-1 inhibitor to show superior OS, along with PFS benefit and an acceptable safety profile, in combination with chemotherapy versus chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. Nivolumab plus chemotherapy … clothes line vector
FDA grants nivolumab accelerated approval for MSI-H or …
WebCheckMate 142 was designed as a phase 2 trial to investigate the activity and safety of nivolumab monotherapy or nivolumab in combination with ipilimumab in patients with … WebJun 29, 2024 · Approval based on Phase 2 CheckMate -142 trial results showing nearly two-thirds of patients responded to the Opdivo plus Yervoy combination with durable responses observed. Opdivo plus Yervoy is the first dual immunotherapy regimen approved in the European Union for colorectal cancer. Opdivo plus Yervoy-based combinations … WebApr 6, 2024 · This study has limitations. In CheckMate 714, the dosage of ipilimumab (1 mg/kg IV every 6 weeks) was based on results from the CheckMate 012 study in advanced NSCLC, 32 in which this dose, in combination with nivolumab 3 mg/kg IV every 2 weeks, was associated with tolerable safety and promising efficacy. While ipilimumab was well … clothes line whirly